BloodCenter of Wisconsin Launches Erythroid Chimerism Test for Monitoring Transplanted Sickle Cell Disease Patients - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
BloodCenter of Wisconsin Launches Erythroid Chimerism Test for Monitoring Transplanted Sickle Cell Disease Patients

BloodCenter of Wisconsin Launches Erythroid Chimerism Test for Monitoring Transplanted Sickle Cell Disease Patients

PR Newswire

MILWAUKEE, Aug. 28, 2014 /PRNewswire-USNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of an innovative Erythroid Chimerism test to monitor erythroid lineage chimerism in patients with sickle cell disease (SCD) following allogeneic bone marrow transplantation. This allows the physician to directly gauge the success of the transplant in these patients and provides physicians with actionable information to guide patient care.

Sickle cell disease is a common and severe autosomal recessive disorder caused by a mutation in the hemoglobin gene. SCD affects approximately 100,000 people in the United States, one in every 300-500 African Americans. In SCD patients with severe clinical symptoms, allogeneic bone marrow transplantation can be used to replace the blood cell producing capacity, potentially curing them of the disease.1

In patients with SCD, several studies have demonstrated that standard chimerism assays do not always reflect chimerism in the erythroid lineage.2,3 Since red cells do not contain DNA, chimerism of the erythroid compartment can be monitored using HbA and HbS transcripts produced from the hemoglobin gene and expressed in red cell progenitors.

"Efficient and accurate monitoring for post-transplant therapy is critical in order to properly manage patient care," said Daniel Bellissimo, Ph.D., director of BloodCenter's Molecular Diagnostic Laboratory. "The addition of BloodCenter's Erythroid Chimerism test reflects its ongoing commitment to advancing patient care by providing physicians worldwide with leading-edge testing in the area of molecular testing."

BloodCenter's Diagnostic Laboratories help physicians provide clinical care to patients worldwide, fostering better understanding and treatment options for patients with difficult-to-diagnose diseases. In addition, the laboratories collaborate with other institutions and industry partners to bring new diagnostic testing and treatment options to patient care.

About BloodCenter of Wisconsin
BloodCenter of Wisconsin is a not-for-profit organization that specializes in blood services, organ, tissue and marrow donation, diagnostic testing, medical services and leading-edge research. BloodCenter of Wisconsin is the only provider of blood to 56 hospitals in 29 Wisconsin counties as well as providing support to hospitals and patients across the country. BloodCenter of Wisconsin advances patient care by delivering life-saving solutions grounded in unparalleled medical and scientific expertise. For more information,visit .


1)      Bernaudin F., Socie G., Kuentz M., Chevret S., Duval M., Bertrand Y., et al. (2007) Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 110: 2749–2756

2)      Wu, Catherine, et al. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Experimental Hematology (2003) 31: 924-933.

3)      Andreanni, Marco et al. Quantitatively different red cell/ nucleated cell chimerism in patient with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica (2011) 96:128-133.

Fay Spano, 414-937-6124

SOURCE BloodCenter of Wisconsin


blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document

Click here